Article
<i>In vivo</i> CRISPR-Cas gene editing with no detectable genome-wide off-target mutations
2018-02-27
Abstract excerpt
CRISPR-Cas genome-editing nucleases hold substantial promise for human therapeutics 1–5 but identifying unwanted off-target mutations remains an important requirement for clinical translation 6, 7 . For ex vivo therapeutic applications, previously published cell-based genome-wide methods provide potentially useful strategies to identify and quantify these off-target mutation sites 8–12 . However, a well-valida...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 12974b0a-42dc-5b86-b984-8d80b6937590
- DOI
- 10.1101/272724
